【24h】

Investigating Side Effects of Existing Drugs Used in Covid-19 Treatment

机译:调查Covid-19治疗中使用的现有药物的副作用

获取原文

摘要

Following the rapid spread and evolution of the novel Corona virus starting in December 2019, the lack of a vaccine or a medication that proved to be effective for Covid-19 was addressed as a major concern by the World Health Organization (WHO), the Center for Disease Control and Prevention (CDC), and the U.S. Food and Drug Administration (FDA) [1]. Accordingly, physicians from countries like China and Korea rushed to provide some potential treatment for Covid-19 from their experience in treating patients of the novel Coronavirus - they used antiviral medications like lopinavir, ritonavir, chloroquine, hydroxychloroquine, ribavirin, interferon, remdesivir, sofosbuvir, nitazoxanide, favipiravir, ivermectin, etc. [1]–[3]. These drugs showed improvement in conditions of Covid-19 patients when used individually, or sometimes using a combination of multiple of them. This does not mean that any combinations of these drugs could be beneficial. Some combinations can be lethal and may lead to increasing health risks or mortality. The drugs are being used in vitro (i.e., on cells in a laboratory for experiments) and vivo (i.e., on humans or animals as clinical trials). In vitro analysis, the chemical structure of the drug and the disease are analyzed to generate a hypothesis on the performance of the drug, then the hypothesis is tested in vivo to measure the actual performance of the drug on a living creature. Although these drugs showed promising results with proper dosage, overdose and incorrect combination with other drugs sometimes proved to be lethal. The effectiveness and side-effects of some of these drugs as reported by recent researchers and trials are described in this paper. We address some related research questions concerning the side effects of the covered drugs and their interaction with other drugs based on some well tested results extracted from approved web sites of drug-drug interactions. The findings are interesting and confirmed favipiravir as the most effective and safe compared to the others, and this coincides with and supports the announcement by Turkish Ministry of Health where favipiravir has been used in treating COVID-19 patients since the early days.
机译:在2019年12月开始的新型电晕病毒的迅速传播和演变之后,缺乏疫苗或证明对Covid-19有效的药物被解决是世界卫生组织(世卫组织),该中心的主要问题用于疾病控制和预防(CDC),以及美国食品和药物管理局(FDA)[1]。因此,来自中国和韩国等国家的医生赶紧为Covid-19提供一些潜在的治疗方法,从他们治疗小冠状病毒的患者的经验中提供了一些潜在的治疗方法 - 他们使用洛诺维尔,ritonavir,氯喹,羟基氯喹,利巴韦林,干扰素,雷德韦尔,Sofosbuvir等抗病毒药物,硝唑烷,Favipiravir,伊维菌素等[1] - [3]。这些药物在单独使用时或有时使用它们的多个组合时,在Covid-19患者的条件下表现出改善。这并不意味着这些药物的任何组合都可能是有益的。一些组合可以是致命的,可能导致健康风险或死亡率增加。该药物用于体外(即,在实验室中的细胞上的细胞中使用)和体内(即人或动物作为临床试验)。体外分析,分析药物和该疾病的化学结构,以产生对药物的性能的假设,然后在体内测试假设以测量药物对生物的实际性能。虽然这些药物表现出具有适当剂量,过量和与其他药物的不正确的组合有前途的结果,但有时被证明是致命的。本文描述了最近的研究人员和试验所报告的这些药物中一些药物的有效性和副作用。我们解决了一些关于涵盖药物的副作用的相关研究问题及其与其他药物的相互作用,基于一些药物 - 药物相互作用的批准网站提取的一些测试结果。结果有趣,并确认了与其他人相比最有效和最有效的,这一点恰逢土耳其卫生部的公告,因为自早期以来,FaviPiravir已被用于治疗Covid-19患者。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号